Published in Immunotherapy Weekly, April 20th, 2005
The quarter, which ended Feb. 28, marks the 48th consecutive profitable quarter from operations for the company. Year-to-date, net income increased 11% to $4,471,000, or $0.53 per share from $0.48 in the prior year.
Year-to-date revenues for the first 9 months of Neogen's 2005 fiscal year were $46,748,000 - a 16% increase from $40,196,000 for the prior year's comparable period. Third quarter revenues were $14,403,000 compared to $14,717,000 in FY 2004.
"While I am proud to report that we remain solidly...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.